CD44 (Phospho-Ser706) Antibody
- Known as:
- CD44 (Phospho-Ser706) Antibody
- Catalog number:
- 11911
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- CD44 (Phospho-Ser706) Antibody
Related genes to: CD44 (Phospho-Ser706) Antibody
- Gene:
- CD44 NIH gene
- Name:
- CD44 molecule (Indian blood group)
- Previous symbol:
- MIC4, MDU2, MDU3
- Synonyms:
- IN, MC56, Pgp1, CD44R, HCELL, CSPG8
- Chromosome:
- 11p13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2019-04-23
Related products to: CD44 (Phospho-Ser706) Antibody
Related articles to: CD44 (Phospho-Ser706) Antibody
- Curcumin and bone marrow-derived mesenchymal stem cells (BMSCs) with osteogenic differentiation potential can promote tendon-bone healing. This study revealed the specific mechanisms by which curcumin promotes osteogenic differentiation of BMSCs. - Source: PubMed
Zeng ZhaoyongBao ZhiqiangZhang JianpingChen XianyiFu XuanjianChen YangCai Daozhang - Previously OTP, CD44 and Ki-67 have been identified as prognostic biomarkers in lung carcinoids (lung neuroendocrine tumors or LNETs). We aimed to assess whether risk profiles can be established using these biomarkers on preoperative LNET biopsies . Patients with LNETs (TNM 8 stage I-III, 2003-2021) who underwent curative resection were selected from Dutch pathology registry (PALGA). Immunohistochemistry for OTP, CD44 and Ki-67 (biomarkers) was performed on matched resection and biopsy (Bx) specimens. Three pathologists revised all cases per the WHO 2021 classification (WHO). OTP and CD44 were assessed by H-score, Ki-67 proliferation index (PI) by eyeball hot-spot scoring. Bx cases diagnosed as carcinoid not otherwise specified (NOS) were considered low risk for relapse and atypical carcinoid (AC) as high risk. Immunostained cases were classified as low risk (OTP≥50, CD44≥30, Ki-67<5%) or high risk (others). Ninety-eight patients were eligible. Nineteen relapse events occurred after a median follow-up of 83 months. The biomarkers correctly identified high risk in 89% (n=17/19) of relapses, outperforming the WHO classification, which assigned 11% (n=2/19) of relapses as AC. Negative predictive value of biomarkers was 0.96 compared to 0.82 for WHO. The biomarkers showed greater prognostic stratification in relapse-free survival analysis and higher inter-observer agreement (biomarkers: κ=0.673; WHO: κ=0.276, both p<0.001). Biomarker expression was more stable between biopsy and resection specimen, improving concordance compared to WHO (biomarkers: κ=0.584, p<0.001; WHO: κ=0.169, p=0.037). In conclusion, an OTP, CD44, and Ki-67 biomarker panel enables reliable identification of low risk LNETs on Bx, outperforming WHO classification for prognostic stratification and biopsy-resection concordance. By accurately identifying tumors with a molecular low risk profile on preoperative biopsies, this panel may help to guide treatment choice for patients considered for sublobar resection. - Source: PubMed
Publication date: 2026/09/21
van Weert Tijmen J JMoonen LauraHillen Lisa Mvon der Thüsen Jan Hden Bakker Michael ALap Lisa M VMarshall Ambar C Evan den Broek EstherDamhuis Ronald ABuikhuisen Wieneke ADingemans Anne-Marie CDerks Jules LSpeel Ernst Jan M - Tumor-targeted and stimuli-responsive nanocarriers have emerged as promising platforms for improving the efficacy and safety of chemotherapy. Herein, we developed a polyethylene glycol- hyaluronic acid-epigallocatechin-3-O-gallate (PEG-HA-EGCG) nanoplatform that integrates polyphenol-mediated drug loading, CD44-targeted delivery, and tumor-responsive doxorubicin (DOX) release. The amphiphilic PEG-HA-EGCG conjugate spontaneously self-assembled into stable micellar nanoparticles comprising a hydrophobic EGCG-rich core and a hydrophilic HA-PEG shell. The abundant aromatic rings and hydroxyl groups of EGCG promoted strong π-π stacking and hydrogen-bonding interactions with DOX, resulting in a high drug-loading efficiency of up to 93% while maintaining nanoparticle stability. Notably, the micelles remained relatively stable under physiological conditions while exhibiting triple-responsive DOX release triggered by acidic pH, reductive conditions, and elevated HAase levels in the tumor microenvironment. The HA shell facilitated CD44 receptor-mediated cellular uptake and enhanced antitumor effects in the 3D spheroid model. Consequently, PEG-HA-EGCG@DOX demonstrated intracellular DOX accumulation and anticancer activity in vitro and achieved tumor growth suppression comparable to free DOX, with reduced systemic toxicity in vivo. These findings demonstrate the potential of PEG-HA-EGCG micelles as a polysaccharide-based nanoplatform integrating high-capacity drug loading, tumor-responsive release, and targeted intracellular delivery for cancer therapy. - Source: PubMed
Publication date: 2026/09/21
Nguyen Dinh TrungNguyen Hoang DuyHoang Anh QuanThi Ngoc Dung DuongTu Quang AnhTruong Minh-DungSai Duc LocPham Dinh-ChuongLe Thi Phuong - Pheochromocytomas (PCCs) in dogs are challenging to diagnose. Plasma proteomics offers a minimally invasive approach to identify circulating biomarkers and disease-relevant pathways. - Source: PubMed
van den Berg Marit FRodríguez-Rojas AlexandroDoulidis Pavlos GPisoni LucianoBurgener Iwan AGalac Sara - Nanodrug delivery systems have shown great potential for tumor therapy but still meet the challenge of precise and efficient targeting. In this work, we demonstrate a hierarchical approach for mitochondria-targeted photothermo-chemotherapy of a breast tumor by fabricating hyaluronic acid (HA)-coated Fe3O4 superparticles (SPs) that are co-loaded with doxorubicin (DOX) and triphenylphosphine (TPP) (Fe3O4-DOX-TPP@HA SPs). As assemblies of Fe3O4 nanoparticles (NPs), the SPs exhibit superparamagnetism and primary tumor tissue targeting with the assistance of an external magnetic field. Meanwhile, the coated HA affords secondary targeting by binding with CD44 high-expressed breast tumor cells. The high level of hyaluronidase in the tumor cell further leads to the degradation of HA and exposure of TPP, thus achieving TPP-mediated tertiary targeting toward mitochondria. In addition, the assembled Fe3O4 NPs endow the SPs with strong photothermal performance, which combines with the loaded DOX to achieve mitochondria-targeted photothermo-chemotherapy of breast tumor models efficiently in vivo. Furthermore, leveraging the superparamagnetism and strong near-infrared absorption of Fe3O4 SPs, multimodal monitoring in tumor therapy by magnetic resonance and photoacoustic imaging is allowed. - Source: PubMed
Publication date: 2026/09/21
Du ShulinLi MengZhang MengsiZheng HaoMiao XiaoLiu ShuweiWang LuZhang Hao